© 2022 MJH Life Sciences and Opthalmology Times Europe. All rights reserved.
© 2022 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
February 16, 2022
At Angiogenesis, Dr David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.
February 14, 2022
A brief overview of findings presented at the 2022 Angiogenesis, Exudation and Degeneration meeting hosted by Bascom Palmer.
February 12, 2022
Investigators in the Netherlands have developed an RNA therapy to halt the progression of Stargardt disease.
Dr Carel Hoyng divulges the main takeaways from his Angiogenesis presentation, including the origins of Stargardt disease, correct diagnosis, ongoing gene therapy trials and the future of therapy.
Dr Carl Regillo discusses the 100-week results of KESTREL and KITE, two pivotal Phase 3 studies for brolucizumab for the treatment of diabetic macular oedema.
Dr Arshad M. Khanani reviews the Phase 2 part A results of the KALAHARI study of THR-149 for the treatment of DMO.
KALAHARI study finds THR-149 to be safe, well-tolerated with preliminary efficacy as treatment for DMO patients who respond suboptimally to anti-VEGF.
During her talk at Angiogenesis, Dr Anat Loewenstein outlines how artificial intelligence could revolutionize diabetic retinopathy screening.
Most patients who had received monthly injections, that is, 92%, preferred the PDS after switching, with 88% having a very strong preference.
Previously treated patients showed significantly reduced treatment burden.